Yu-Bin Kim

Yu-Bin Kim

Auto-generated profile, based on publicly available information

Yu-Bin Kim

Research Institute, Nano Intelligent Biomedical Engineering Corporation (NIBEC), Seoul, 03127, Republic of Korea

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2026 in Biomaterials
Verified
Journal Article
Open access
HJHayoon Jeong
Hayoon Jeong
GYGookjin Yoon
Gookjin Yoon
DLDong Woo Lee
Dong Woo Lee
HYHansang Yu
Hansang Yu
YKYu-Bin Kim
Yu-Bin Kim
YPYoon Jeong Park
Yoon Jeong Park
Messenger RNA (mRNA) vaccines require efficient delivery systems to reach antigen-presenting cells (APCs). Lipid nanoparticles (LNPs) are a standard delivery carrier. However, LNPs often accumulate in the liver and exhibit transient protein expression. These limitations can restrict their safety and immunogenic potential. Here, we developed a modular, peptide-based nanocomplex to overcome the current limitations. The system comprises three functional peptides: an RNA-binding peptide (RBP) for condensation, l-polyglutamic acid (PGA) for charge modulation, and an APC-targeting cell-penetrating peptide (A-CPP). This A-CPP features a newly discovered 7-mer immune cell-binding motif identified in this study. We optimized the physicochemical properties by systematically fine-tuning the ratios of these peptide modules. The optimized nanocomplex formed stable particles under 200 nm. Unlike LNPs, which showed significant liver accumulation, the peptide-nanocomplexes remained localized at the injection site and effectively drained to the lymph nodes. Furthermore, the peptide-nanocomplex retained mRNA expression for up to 7 days in vivo, whereas LNP-mediated expression diminished within 48 h. In mice immunized with SARS-CoV-2 spike mRNA, this prolonged antigen exposure elicited robust neutralizing antibody titers comparable to LNPs. Notably, the peptide-nanocomplex induced significantly higher CD8+ T cell responses than LNPs. Moreover, the peptide-nanocomplex demonstrated an excellent safety profile in vivo with no toxicity observed even after daily injections for two weeks at doses up to 200 times higher. This study establishes a data-driven fine-tuning strategy for peptide-based mRNA delivery. The resulting peptide-nanocomplex offers a safer, lymph node-targeted, and longer-lasting efficacy alternative to lipid-based carriers for next-generation vaccines.

10 March 2026 in Clinical Implant Dentistry and Related Research
Verified
Journal Article
Open access
HHHee‐Seung Han
Hee‐Seung Han
DLDong Woo Lee
Dong Woo Lee
YKYu‐Bin Kim
Yu‐Bin Kim
SSSanghui Seok
Sanghui Seok
JPJeong Yeon Park
Jeong Yeon Park
YCYoung-Dan Cho
Young-Dan Cho
Objectives: This study compared the osteogenic mechanisms and preclinical efficacy of bone morphogenetic protein 9 (BMP9) and BMP2 in vitro and in a beagle peri‐implant defect model in vivo. Materials and Methods: In vitro, MC3T3‐E1 preosteoblasts were treated with BMP2 or BMP9 to assess osteogenic gene expression ( Col1, Runx2, Alp, Ocn ) by real‐time PCR, Smad1/5/9 phosphorylation by western blotting, and osteogenesis by alkaline phosphatase (ALP) and Alizarin Red S staining. In vivo, saddle‐type peri‐implant defects were created in beagle mandibles and treated with a collagenated xenograft matrix with or without BMP2 or BMP9 (150 μg/site). After 8 weeks, implant stability, micro‐CT, histomorphometry, and osseointegration parameters were analyzed. Results: BMP9 significantly enhanced osteogenic gene expression, Smad1/5/9 phosphorylation, ALP activity, and mineralization compared to BMP2. In vivo, BMP9 yielded the highest implant stability values, greater defect fill, and higher bone volume fraction, bone mineral density, and bone‐to‐implant contact. Conclusions: BMP9 showed stronger osteoinductive potential than BMP2, resulting in improved bone regeneration and osseointegration. These findings suggest that BMP9 is a promising growth factor for improving dental implant outcomes.